4 withdrawn, 2 active not recruiting, 2 completed, 2 no longer available. 9 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Withdrawn 4, Active not recruiting 2, Completed 1, Recruiting 1, Terminated 1 |
| Phase 1 | 4 | Active not recruiting 2, Completed 2 |
Follow Implicit Bioscience: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients Atibuclimab, Placebo - Acute Respiratory Distress Syndrome, Adult Respiratory Distress Syndrome | Phase 2 | Recruiting | Implicit Bioscience | 56 | 2026-06-17 | 2026-07-29 |
| Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI Atibuclimab (IC14), 20 mg/kg intravenously, once, Placebo, 150 mL intravenously, once - STEMI, STEMI (ST Elevation MI) | Phase 1 / Phase 2 | Active not recruiting | Implicit Bioscience | 10 | 2025-02-06 | 2026-03-27 |
| IC14 for Treatment of Acute Decompensated Heart Failure Atibuclimab (IC14) - Acute Decompensated Heart Failure | Phase 1 / Phase 2 | Active not recruiting | Implicit Bioscience | 10 | 2024-10-17 | 2026-03-27 |
| IC14 (Atibuclimab) in Arrhythmogenic Cardiomyopathy IC14 - Arrhythmogenic Right Ventricular Dysplasia, Arrhythmogenic Left Ventricular Cardiomyopathy | Phase 1 / Phase 2 | Completed | Implicit Bioscience | 1 | 2024-03-29 | 2026-04-22 |
| IC14 for Treatment of Amyotrophic Lateral Sclerosis IC14, Placebo - Amyotrophic Lateral Sclerosis, Motor Neuron Disease | Phase 2 | Withdrawn | Implicit Bioscience | 2021-08-15 | 2026-05-05 | |
| COVID-19 and Anti-CD14 Treatment Trial anti-CD14, Placebo, remdesivir - Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) | Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 49 | 2021-04-12 | 2023-06-26 |
| IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS) Biologic: IC14 (monoclonal antibody against human CD14) - Amyotrophic Lateral Sclerosis | Phase 2 | Withdrawn | Implicit Bioscience | 2019-09-01 | 2026-05-05 | |
| A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome IC14, Placebo - Acute Respiratory Distress Syndrome | Phase 2 | Withdrawn | Implicit Bioscience | 2019-06-01 | 2026-05-05 | |
| IC14 in Adult Patients With Dengue Fever IC14, Placebo - Dengue Fever | Phase 2 | Withdrawn | Implicit Bioscience | 2019-05-01 | 2026-05-05 | |
| Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease IC14 - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 1 | Completed | Implicit Bioscience | 10 | 2017-10-01 | 2025-08-20 |
| Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19) IC14, a monoclonal antibody against CD14 - COVID, ARDS, Human | No longer available | Implicit Bioscience | 2021-06-21 | |||
| IC14 for ALS Patients Expanded Access IC14 - Amyotrophic Lateral Sclerosis | No longer available | Implicit Bioscience | 2025-08-20 |
Amyotrophic Lateral Sclerosis (4) · Respiratory Distress Syndrome (3) · Acute Lung Injury (2) · Motor Neuron Disease (2) · Arrhythmias, Cardiac (1) · Arrhythmogenic Right Ventricular Dysplasia (1) · Arrhythmogenic Right Ventricular Dysplasia, Familial, 1 (1) · COVID-19 (1) · Coronavirus Infections (1) · Dengue (1) · Heart Failure (1) · ST Elevation Myocardial Infarction (1)
atibuclimab (4) · remdesivir (1)
United States (6) · Australia (3) · Italy (1)
Jan Agosti, MD (4) · Antonio Abbate, MD (1) · Antonio Abbate, MD, PhD (1) · Linzee Mabrey, MD, MsC (1) · Marc Sintek, MD (1) · Mark M. Wurfel, MD, PhD (1) · Robert D Henderson, MBBS (1) · Robert D. Henderson, MBBS (1) · Thomas R. Martin, MD (1)
UM1AI109565 (1)